clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with clarithromycin
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Stjepanovic MI et al. | Pulmonary and Vertebral Mycobacterium avium Disease in a HIV-negative 71-year-old Man - A Case Report. | 2016 | Infez Med | pmid:28011973 |
Muñoz-Egea MC et al. | Effect of Antibiotics and Antibiofilm Agents in the Ultrastructure and Development of Biofilms Developed by Nonpigmented Rapidly Growing Mycobacteria. | 2016 | Microb. Drug Resist. | pmid:26208145 |
Salimi A et al. | Toxicity of macrolide antibiotics on isolated heart mitochondria: a justification for their cardiotoxic adverse effect. | 2016 | Xenobiotica | pmid:26068526 |
Losurdo G et al. | Role of concomitant therapy for eradication: A technical note. | 2016 | World J. Gastroenterol. | pmid:27784977 |
Zycinska K et al. | Antibiotic Treatment of Hospitalized Patients with Pneumonia Complicated by Clostridium Difficile Infection. | 2016 | Adv. Exp. Med. Biol. | pmid:27620311 |
Bax HI et al. | Tigecycline Potentiates Clarithromycin Activity against Mycobacterium avium In Vitro. | 2016 | Antimicrob. Agents Chemother. | pmid:26883697 |
Hirata Y et al. | Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen. | 2016 | Int. J. Infect. Dis. | pmid:27590563 |
Liou JM et al. | Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. | 2016 | Lancet | pmid:27769562 |
Campillo A et al. | [10-day triple therapy with esomeprazole 40 mg/12 h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection]. | 2016 | Gastroenterol Hepatol | pmid:27084668 |
Chauffour A et al. | Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice. | 2016 | PLoS Negl Trop Dis | pmid:27755552 |
Abuhammour A et al. | Standard triple therapy versus sequential therapy for eradication of Helicobacter pylori in treatment naïve and retreat patients. | 2016 | Arab J Gastroenterol | pmid:27665525 |
Matsumoto H et al. | Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. | 2016 | Dig. Dis. Sci. | pmid:27659671 |
Zhou L et al. | Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial. | 2016 | Helicobacter | pmid:26104022 |
Rossi A et al. | Floating modular drug delivery systems with buoyancy independent of release mechanisms to sustain amoxicillin and clarithromycin intra-gastric concentrations. | 2016 | Drug Dev Ind Pharm | pmid:26065531 |
Bugli F et al. | In vitro effect of clarithromycin and alginate lyase against helicobacter pylori biofilm. | 2016 | Biotechnol. Prog. | pmid:27535356 |
Shichijo S et al. | Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice. | 2016 | J Dig Dis | pmid:27534444 |
Morimoto K et al. | Macrolide-Resistant Mycobacterium avium Complex Lung Disease: Analysis of 102 Consecutive Cases. | 2016 | Ann Am Thorac Soc | pmid:27513168 |
Christianson S et al. | Time-to-Detection of Inducible Macrolide Resistance in Mycobacterium abscessus Subspecies and Its Association with the Erm(41) Sequevar. | 2016 | PLoS ONE | pmid:27490181 |
Harada T et al. | Premedication with Clarithromycin Is Effective against Secondary Bacterial Pneumonia during Influenza Virus Infection in a Pulmonary Emphysema Mouse Model. | 2016 | J. Pharmacol. Exp. Ther. | pmid:27489022 |
Bonfigli AR et al. | Randomized, double-blind, placebo-controlled trial to evaluate the effect of Helicobacter pylori eradication on glucose homeostasis in type 2 diabetic patients. | 2016 | Nutr Metab Cardiovasc Dis | pmid:27480449 |
Lotfipour F et al. | Study of Antimicrobial Effects of Clarithromycin Loaded PLGA Nanoparticles against Clinical Strains of Helicobacter pylori. | 2016 | Drug Res (Stuttg) | pmid:25919643 |
Miyaki A et al. | An assessment of the efficacy of first-line Helicobacter pylori-eradication therapy based on clarithromycin susceptibility. | 2016 | Minerva Gastroenterol Dietol | pmid:27304198 |
Okano Y et al. | Miliary pulmonary nodules due to Mycobacterium xenopi in a steroid-induced immunocompromised patient successfully treated with chemotherapy: a case report. | 2016 | BMC Pulm Med | pmid:27287608 |
Steurer J | [Months of antibiotic therapy in persistent symptoms of Lyme disease without effect]. | 2016 | Praxis (Bern 1994) | pmid:27269781 |
Chung JW et al. | Ten-day empirical sequential or concomitant therapy is more effective than triple therapy for Helicobacter pylori eradication: A multicenter, prospective study. | 2016 | Dig Liver Dis | pmid:27257049 |
Mitchell H and Katelaris P | Epidemiology, clinical impacts and current clinical management of Helicobacter pylori infection. | 2016 | Med. J. Aust. | pmid:27256648 |
Ullah S et al. | Development of a biocompatible creatinine-based niosomal delivery system for enhanced oral bioavailability of clarithromycin. | 2016 | Drug Deliv | pmid:27247018 |
Parize P et al. | Induction therapy with linezolid/clarithromycin combination for Mycobacterium chelonae skin infections in immunocompromised hosts. | 2016 | J Eur Acad Dermatol Venereol | pmid:25677464 |
Akram FE et al. | A combination of silver nanoparticles and visible blue light enhances the antibacterial efficacy of ineffective antibiotics against methicillin-resistant Staphylococcus aureus (MRSA). | 2016 | Ann. Clin. Microbiol. Antimicrob. | pmid:27530257 |
Bilgilier C et al. | Prevalence of clarithromycin-resistant Helicobacter pylori strains in gastric mucosa-associated lymphoid tissue lymphoma patients. | 2016 | Ann. Hematol. | pmid:27091350 |
Root AA et al. | Evaluation of the risk of cardiovascular events with clarithromycin using both propensity score and self-controlled study designs. | 2016 | Br J Clin Pharmacol | pmid:27090996 |
Kazama I et al. | Clarithromycin Dose-Dependently Stabilizes Rat Peritoneal Mast Cells. | 2016 | Chemotherapy | pmid:27088971 |
Huynh VA et al. | [Fixed drug eruption to clarithromycin: The importance of challenge tests in diagnosis]. | 2016 | Ann Dermatol Venereol | pmid:27080820 |
EmiralioÄŸlu N et al. | Pulmonary Mycobacterium abscessus Infection in a Patient with Triple A Syndrome. | 2016 | J. Trop. Pediatr. | pmid:27080471 |
Graham DY and Dore MP | Helicobacter pylori therapy: a paradigm shift. | 2016 | Expert Rev Anti Infect Ther | pmid:27077447 |
Song ZQ et al. | Hybrid Therapy Regimen for Helicobacter Pylori Eradication. | 2016 | Chin. Med. J. | pmid:27064046 |
Matsumoto H et al. | Molecular Detection of H. pylori Using Adherent Gastric Mucous to Biopsy Forceps. | 2016 | Helicobacter | pmid:27061611 |
Tsaganos T et al. | Clarithromycin Leads to Long-Term Survival and Cost Benefit in Ventilator-Associated Pneumonia and Sepsis. | 2016 | Antimicrob. Agents Chemother. | pmid:27044546 |
Friedman ND et al. | Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort. | 2016 | Antimicrob. Agents Chemother. | pmid:26883709 |
Chua CS et al. | The efficacy of blueberry and grape seed extract combination on triple therapy for Helicobacter pylori eradication: a randomised controlled trial. | 2016 | Int J Food Sci Nutr | pmid:26883189 |
Meng X et al. | [Antibiotic resistance of Helicobacter pylori clinical isolates in Hebei Province]. | 2016 | Zhonghua Yi Xue Za Zhi | pmid:26879786 |
Bakshi SS | Outcome evaluation of clarithromycin, metronidazole and lansoprazole regimens in Helicobacter pylori positive or negative children with resistant otitis media with effusion. | 2016 | J Laryngol Otol | pmid:26878377 |
Franceschi F et al. | High dose amoxicillin-based first line regimen is equivalent to sequential therapy in the eradication of H. pylori infection. | 2016 | Eur Rev Med Pharmacol Sci | pmid:26875899 |
Tepeš B et al. | Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication. | 2016 | Eur J Gastroenterol Hepatol | pmid:26862930 |
Lim SG et al. | The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use. | 2016 | Dig Liver Dis | pmid:26856963 |
Mukai S et al. | Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines. | 2016 | Int. J. Oncol. | pmid:26718641 |
Hassan ST et al. | In vitro synergistic effect of Hibiscus sabdariffa aqueous extract in combination with standard antibiotics against Helicobacter pylori clinical isolates. | 2016 | Pharm Biol | pmid:26731378 |
Çağan-Appak Y et al. | Clarithromycin resistance and 23S rRNA gene point mutations of Helicobacter pylori infection in children. | 2016 | Turk. J. Pediatr. | pmid:28276208 |
Thung I et al. | Review article: the global emergence of Helicobacter pylori antibiotic resistance. | 2016 | Aliment. Pharmacol. Ther. | pmid:26694080 |
Vermeer LM et al. | Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters. | 2016 | Drug Metab. Dispos. | pmid:26668209 |
Meng Y et al. | Multi-functional Liposomes Enhancing Target and Antibacterial Immunity for Antimicrobial and Anti-Biofilm Against Methicillin-Resistant Staphylococcus aureus. | 2016 | Pharm. Res. | pmid:26666773 |
Kamiya K et al. | Erythema multiforme caused by triple therapy with amoxicillin, clarithromycin and vonoprazan for Helicobacter pylori. | 2016 | J. Dermatol. | pmid:26508502 |
Mark TM and Coleman M | It's Time to Take Clarithromycin Seriously in Multiple Myeloma. | 2016 | Acta Haematol. | pmid:26505907 |
Qiu XH et al. | Clarithromycin Synergistically Enhances Thalidomide Cytotoxicity in Myeloma Cells. | 2016 | Acta Haematol. | pmid:26505646 |
Lee J et al. | A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM. | 2016 | J. Matern. Fetal. Neonatal. Med. | pmid:26373262 |
Tsujimae M et al. | A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori. | 2016 | Digestion | pmid:28030862 |
Koh WJ et al. | Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease. | 2017 | Clin. Infect. Dis. | pmid:28011608 |
Çekin AH et al. | Use of probiotics as an adjuvant to sequential H. pylori eradication therapy: impact on eradication rates, treatment resistance, treatment-related side effects, and patient compliance. | 2017 | Turk J Gastroenterol | pmid:28007678 |
Ikeue T et al. | Pleuritis Caused by Mycobacterium kyorinense without Pulmonary Involvement. | 2017 | Intern. Med. | pmid:28924121 |
Yamamoto S et al. | Mitochondrial proteins NIP-SNAP-1 and -2 are a target for the immunomodulatory activity of clarithromycin, which involves NF-κB-mediated cytokine production. | 2017 | Biochem. Biophys. Res. Commun. | pmid:27998764 |
Panozzo C et al. | Chemicals or mutations that target mitochondrial translation can rescue the respiratory deficiency of yeast bcs1 mutants. | 2017 | Biochim. Biophys. Acta | pmid:28888990 |
Santos MA et al. | Nothing to (S)cough at: Pulmonary Mycobacterium avium Complex Infection. | 2017 | Am. J. Med. | pmid:27984010 |
Smibert OC et al. | Short Communication: Mycobacterium avium Complex Infection and Immune Reconstitution Inflammatory Syndrome Remain a Challenge in the Era of Effective Antiretroviral Therapy. | 2017 | AIDS Res. Hum. Retroviruses | pmid:28791872 |
Hiroi S et al. | Impact of health insurance coverage for gastritis on the trends in eradication therapy in Japan: retrospective observational study and simulation study based on real-world data. | 2017 | BMJ Open | pmid:28760790 |
Jenkins H et al. | Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study. | 2017 | Clin Drug Investig | pmid:27928738 |
Takemoto Y et al. | Disseminated Mycobacterium scrofulaceum Infection in an Immunocompetent Host. | 2017 | Intern. Med. | pmid:28717096 |
Alba C et al. | Antibiotic resistance in Helicobacter pylori. | 2017 | Curr. Opin. Infect. Dis. | pmid:28704226 |
Mishima E et al. | Acute Kidney Injury from Excessive Potentiation of Calcium-channel Blocker via Synergistic CYP3A4 Inhibition by Clarithromycin Plus Voriconazole. | 2017 | Intern. Med. | pmid:28674358 |
Shimoyama T et al. | Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens. | 2017 | Intern. Med. | pmid:28674348 |
Stieler Stewart AL et al. | Effects of clarithromycin, azithromycin and rifampicin on terbutaline-induced sweating in foals. | 2017 | Equine Vet. J. | pmid:28238211 |
Emmanuel R et al. | Antimicrobial efficacy of drug blended biosynthesized colloidal gold nanoparticles from Justicia glauca against oral pathogens: A nanoantibiotic approach. | 2017 | Microb. Pathog. | pmid:29101061 |
Bichler EK et al. | Clarithromycin increases neuronal excitability in CA3 pyramidal neurons through a reduction in GABAergic signaling. | 2017 | J. Neurophysiol. | pmid:27733592 |
Tsugawa K et al. | Clarithromycin attenuates the expression of monocyte chemoattractant protein-1 by activating toll-like receptor 4 in human mesangial cells. | 2017 | Clin. Exp. Nephrol. | pmid:27614743 |
Okuda M et al. | Nationwide survey of Helicobacter pylori treatment for children and adolescents in Japan. | 2017 | Pediatr Int | pmid:27223686 |
Bewick J et al. | The value of a feasibility study into long-term macrolide therapy in chronic rhinosinusitis. | 2017 | Clin Otolaryngol | pmid:27223120 |
Chang KH et al. | Comparison of antibiotic regimens in preterm premature rupture of membranes: neonatal morbidity and 2-year follow-up of neurologic outcome. | 2017 | J. Matern. Fetal. Neonatal. Med. | pmid:27687157 |
Abadi ATB | Resistance to clarithromycin and gastroenterologist's persistence roles in nomination for Helicobacter pylori as high priority pathogen by World Health Organization. | 2017 | World J. Gastroenterol. | pmid:29085187 |
Pastukh N et al. | GenoType® HelicoDR test in comparison with histology and culture for Helicobacter pylori detection and identification of resistance mutations to clarithromycin and fluoroquinolones. | 2017 | Helicobacter | pmid:29058343 |
Tognetti L et al. | Bullous impetigo during interstitial pneumonitis. | 2017 | G Ital Dermatol Venereol | pmid:29050448 |
Gunnarsdottir AI et al. | Antibiotic susceptibility of Helicobacter pylori in Iceland. | 2017 | Infect Dis (Lond) | pmid:28440099 |
Manniello MD et al. | Clarithromycin and N-acetylcysteine co-spray-dried powders for pulmonary drug delivery: A focus on drug solubility. | 2017 | Int J Pharm | pmid:28377314 |
Van der Paardt AL et al. | Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis. | 2017 | Eur. Respir. J. | pmid:28331034 |
Souto Filho JTD et al. | Long-term complete remission of primary gastric plasmacytoma following endoscopic resection. | 2017 | Ann. Hematol. | pmid:28315923 |
Antonakos N et al. | Decreased cytokine production by mononuclear cells after severe gram-negative infections: early clinical signs and association with final outcome. | 2017 | Crit Care | pmid:28274246 |
Radzikowska E et al. | Cryptogenic organizing pneumonia-Results of treatment with clarithromycin versus corticosteroids-Observational study. | 2017 | PLoS ONE | pmid:28945804 |
Chew KL et al. | Predominance of clarithromycin-susceptible Mycobacterium massiliense subspecies: Characterization of the Mycobacterium abscessus complex at a tertiary acute care hospital. | 2017 | J. Med. Microbiol. | pmid:28874233 |
Miura S et al. | [Effective BiRd Therapy after the Addition of Clarithromycin for Lenalidomide and Dexamethasone Resistant Multiple Myeloma Ineligible for Stem Cell Transplantation]. | 2017 | Gan To Kagaku Ryoho | pmid:28860442 |
McCallum GB et al. | Antibiotics for persistent cough or wheeze following acute bronchiolitis in children. | 2017 | Cochrane Database Syst Rev | pmid:28828759 |
de Ãvila BE et al. | Micromotor-enabled active drug delivery for in vivo treatment of stomach infection. | 2017 | Nat Commun | pmid:28814725 |
Zhang D et al. | Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial. | 2017 | Medicine (Baltimore) | pmid:28796053 |
Fraser AG | Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. | 2017 | Aliment. Pharmacol. Ther. | pmid:28776748 |
Jung YS et al. | Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori-authors' reply. | 2017 | Aliment. Pharmacol. Ther. | pmid:28776746 |
Turvey SL et al. | Mycobacterium branderi infection: Case report and literature review of an unusual and difficult-to-treat non-tuberculous mycobacterium. | 2017 | Int. J. Infect. Dis. | pmid:28268125 |
Kadota JI et al. | The clinical efficacy of a clarithromycin-based regimen for Mycobacterium avium complex disease: A nationwide post-marketing study. | 2017 | J. Infect. Chemother. | pmid:28254517 |
Ufuk A et al. | In Vitro and in Silico Tools To Assess Extent of Cellular Uptake and Lysosomal Sequestration of Respiratory Drugs in Human Alveolar Macrophages. | 2017 | Mol. Pharm. | pmid:28252969 |
Iwayama K et al. | Long-term treatment of clarithromycin at a low concentration improves hydrogen peroxide-induced oxidant/antioxidant imbalance in human small airway epithelial cells by increasing Nrf2 mRNA expression. | 2017 | BMC Pharmacol Toxicol | pmid:28235416 |
Komiya K et al. | Clarithromycin attenuates IL-13-induced periostin production in human lung fibroblasts. | 2017 | Respir. Res. | pmid:28219384 |
Sakurai K et al. | Comparative study: Vonoprazan and proton pump inhibitors in eradication therapy. | 2017 | World J. Gastroenterol. | pmid:28216974 |
Awan S et al. | Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study. | 2017 | Lung Cancer | pmid:28213005 |
Quinn KL et al. | Macrolides, Digoxin Toxicity and the Risk of Sudden Death: A Population-Based Study. | 2017 | Drug Saf | pmid:28421551 |